68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer
Clinical Nuclear Medicine. 2019-09-01; 44(9): e535-e536
Read on PubMed
1. Clin Nucl Med. 2019 Sep;44(9):e535-e536. doi: 10.1097/RLU.0000000000002672.
68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial
Staging of High-Risk Prostate Cancer.
Schollhammer R(1), de Clermont Gallerande H(1), Robert G(2), Yacoub M(3), Vimont
D(1), Hindié E(1), Fernandez P(1), Morgat C(1).
(1)From the Nuclear Medicine Department, University Hospital of Bordeaux and
INCIA, University of Bordeaux.
(2)Departments of Urology.
(3)Pathology, University Hospital of Bordeaux, Bordeaux, France.
Ga-labeled prostate-specific membrane antigen inhibitors and Ga-labeled
gastrin-releasing peptide receptor antagonists showed interesting results for
staging biochemically recurrent prostate cancer. In this case,
Ga-prostate-specific membrane antigen-617 PET/CT, Ga-RM2 PET/CT, and F-choline
PET/CT were performed in a patient (66-year-old man, prostate-specific antigen =
6.7 ng/mL) with biopsy-proven Gleason 9 (5 + 4) prostate cancer, candidate for
radical prostatectomy and lymph node dissection.
PMID: 31246685 [Indexed for MEDLINE]